JOURNAL ARTICLE

FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma With Susceptible IDH1 or IDH2 Variants.

  • Published In: ONS Voice, 2024. P. 3 1 of 2

  • Database: Academic Search Ultimate 2 of 2

Abstract

The article focuses on the Food and Drug Administration (FDA) approval of Vorasidenib for treating Grade 2 astrocytoma or oligodendroglioma with susceptible IDH1 or IDH2 variants. Topics include the drug's mechanism of action, its role in treating these specific gliomas, and the clinical significance of the IDH1/2 mutations in patient outcomes.

Additional Information

  • Source:ONS Voice. 2024/08, p3
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • ISSN:2475-6938
  • Accession Number:182128715

Looking to go deeper into this topic? Look for more articles on EBSCOhost.